Cargando…
The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis
BACKGROUND: Major depressive disorder causes a great burden on patients and societies. Venlafaxine and mirtazapine are commonly prescribed as second-line treatment for patients with major depressive disorder worldwide. Previous systematic reviews have concluded that venlafaxine and mirtazapine reduc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061867/ https://www.ncbi.nlm.nih.gov/pubmed/36991504 http://dx.doi.org/10.1186/s13643-023-02221-5 |
_version_ | 1785017380356751360 |
---|---|
author | Jørgensen, Caroline Kamp Juul, Sophie Siddiqui, Faiza Horowitz, Mark Abie Moncrieff, Joanna Munkholm, Klaus Hengartner, Michael Pascal Kirsch, Irving Gluud, Christian Jakobsen, Janus Christian |
author_facet | Jørgensen, Caroline Kamp Juul, Sophie Siddiqui, Faiza Horowitz, Mark Abie Moncrieff, Joanna Munkholm, Klaus Hengartner, Michael Pascal Kirsch, Irving Gluud, Christian Jakobsen, Janus Christian |
author_sort | Jørgensen, Caroline Kamp |
collection | PubMed |
description | BACKGROUND: Major depressive disorder causes a great burden on patients and societies. Venlafaxine and mirtazapine are commonly prescribed as second-line treatment for patients with major depressive disorder worldwide. Previous systematic reviews have concluded that venlafaxine and mirtazapine reduce depressive symptoms, but the effects seem small and may not be important to the average patient. Moreover, previous reviews have not systematically assessed the occurrence of adverse events. Therefore, we aim to investigate the risks of adverse events with venlafaxine or mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder in two separate systematic reviews. METHODS: This is a protocol for two systematic reviews with meta-analysis and Trial Sequential Analysis. The assessments of the effects of venlafaxine or mirtazapine will be reported in two separate reviews. The protocol is reported as recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, risk of bias will be assessed with the Cochrane risk-of-bias tool version 2, clinical significance will be assessed using our eight-step procedure, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach. We will search for published and unpublished trials in major medical databases and trial registers. Two review authors will independently screen the results from the literature searches, extract data, and assess risk of bias. We will include published or unpublished randomised clinical trial comparing venlafaxine or mirtazapine with ‘active placebo’, placebo, or no intervention for adults with major depressive disorder. The primary outcomes will be suicides or suicide attempts, serious adverse events, and non-serious adverse events. Exploratory outcomes will include depressive symptoms, quality of life, and individual adverse events. If feasible, we will assess the intervention effects using random-effects and fixed-effect meta-analyses. DISCUSSION: Venlafaxine and mirtazapine are frequently used as second-line treatment of major depressive disorder worldwide. There is a need for a thorough systematic review to provide the necessary background for weighing the benefits against the harms. This review will ultimately inform best practice in the treatment of major depressive disorder. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022315395. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-023-02221-5. |
format | Online Article Text |
id | pubmed-10061867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100618672023-03-31 The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis Jørgensen, Caroline Kamp Juul, Sophie Siddiqui, Faiza Horowitz, Mark Abie Moncrieff, Joanna Munkholm, Klaus Hengartner, Michael Pascal Kirsch, Irving Gluud, Christian Jakobsen, Janus Christian Syst Rev Protocol BACKGROUND: Major depressive disorder causes a great burden on patients and societies. Venlafaxine and mirtazapine are commonly prescribed as second-line treatment for patients with major depressive disorder worldwide. Previous systematic reviews have concluded that venlafaxine and mirtazapine reduce depressive symptoms, but the effects seem small and may not be important to the average patient. Moreover, previous reviews have not systematically assessed the occurrence of adverse events. Therefore, we aim to investigate the risks of adverse events with venlafaxine or mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder in two separate systematic reviews. METHODS: This is a protocol for two systematic reviews with meta-analysis and Trial Sequential Analysis. The assessments of the effects of venlafaxine or mirtazapine will be reported in two separate reviews. The protocol is reported as recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, risk of bias will be assessed with the Cochrane risk-of-bias tool version 2, clinical significance will be assessed using our eight-step procedure, and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach. We will search for published and unpublished trials in major medical databases and trial registers. Two review authors will independently screen the results from the literature searches, extract data, and assess risk of bias. We will include published or unpublished randomised clinical trial comparing venlafaxine or mirtazapine with ‘active placebo’, placebo, or no intervention for adults with major depressive disorder. The primary outcomes will be suicides or suicide attempts, serious adverse events, and non-serious adverse events. Exploratory outcomes will include depressive symptoms, quality of life, and individual adverse events. If feasible, we will assess the intervention effects using random-effects and fixed-effect meta-analyses. DISCUSSION: Venlafaxine and mirtazapine are frequently used as second-line treatment of major depressive disorder worldwide. There is a need for a thorough systematic review to provide the necessary background for weighing the benefits against the harms. This review will ultimately inform best practice in the treatment of major depressive disorder. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022315395. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13643-023-02221-5. BioMed Central 2023-03-30 /pmc/articles/PMC10061867/ /pubmed/36991504 http://dx.doi.org/10.1186/s13643-023-02221-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Protocol Jørgensen, Caroline Kamp Juul, Sophie Siddiqui, Faiza Horowitz, Mark Abie Moncrieff, Joanna Munkholm, Klaus Hengartner, Michael Pascal Kirsch, Irving Gluud, Christian Jakobsen, Janus Christian The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
title | The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
title_full | The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
title_fullStr | The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
title_full_unstemmed | The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
title_short | The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis |
title_sort | risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and trial sequential analysis |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061867/ https://www.ncbi.nlm.nih.gov/pubmed/36991504 http://dx.doi.org/10.1186/s13643-023-02221-5 |
work_keys_str_mv | AT jørgensencarolinekamp therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT juulsophie therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT siddiquifaiza therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT horowitzmarkabie therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT moncrieffjoanna therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT munkholmklaus therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT hengartnermichaelpascal therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT kirschirving therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT gluudchristian therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT jakobsenjanuschristian therisksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT jørgensencarolinekamp risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT juulsophie risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT siddiquifaiza risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT horowitzmarkabie risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT moncrieffjoanna risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT munkholmklaus risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT hengartnermichaelpascal risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT kirschirving risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT gluudchristian risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis AT jakobsenjanuschristian risksofadverseeventswithvenlafaxineandmirtazapineversusactiveplaceboplaceboornointerventionforadultswithmajordepressivedisorderaprotocolfortwoseparatesystematicreviewswithmetaanalysisandtrialsequentialanalysis |